Detail akcie Relay Therapetcs Rg online

Business Summary: Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3K?), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3K?.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Relay Therapeutics Inc revenues decreased 16% to $8.4M. Net loss decreased 15% to $221.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.94 to -$1.30.